Fig 4. ssAAV2-STC-1-FLAG reduces IOP compared to ssAAV2-GFP.
A) After baseline IOP measurements, ssAAV2-STC-1-FLAG (3x109 VGs) was injected in one eye and ssAAV2-GFP (3x109 VGs) was injected into the fellow eye (n = 22) of 3-month-old C57BL/6J mice. IOP was lowered by week 1. At the end of week 8, remaining mice in the study (n = 8) were randomized to continue without further treatment (n = 4) or receive a second injection (n = 4). By the end of week 16, there was no detectable difference in IOP lowering between once-injected and twice-injected ssAAV2-STC-1-FLAG treated mice. B) Similar data presented in a bar graph format with statistical analysis performed bi-monthly post-injection.